in this issue
Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients
Xellia expands into the US by acquiring manufacturing plant
July 7, 2014 | Natasha Alperowicz
Xellia Pharmaceuticals (Copenhagen), a world-leading producer of active pharma ingredients (APIs) and finished dosage forms, today announced it has acquired Fresenius Kabi’s (Lake Zurich, IL) dedicated lyophilized (freeze-dried) vial manufacturing facility at Raleigh, NC. The deal includes a continuous manufacturing and supply agreement with Fresenius Kabi's US arm. Financial details have not been disclosed. The manufacturing site is located close to the Research Triangle Park and is Xellia’s first facility in the United States, significantly...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee